Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.
Adecatumumab (4 μM; 18 h) shows diverse kinetic binding activities among human Adecatumumab and murine Adecatumumab in B16/EpCAM 3E3 cells[2].Adecatumumab (0.1 ng/mL-0.1 mg/mL; 4 h) shows a dose-dependent Antibodies depend on cell-mediated cytotoxicity (ADCC) activity in natural killing (NK) cells[2].
Adecatumumab (300 μg/mouse; i.v. bolus injection; 3 times per week) inhibits tumor growth in B16/EpCAM xenograft tumor model in mice, both of human adecatumumab and mu-adecatumumab[2].Both human adecatumumab and mu-adecatumumab (300 μg/mouse; i.v. bolus injection; single dose) exhibit a bi-exponential curve progression of serum concentration with an early distribution phase between 0 and 10 h and a terminal elimination phase[2].
References:
[1]. Kurtz JE, et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
[2]. Lutterbuese P, et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007 Apr;56(4):459-68.